Cesium API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Cesium | CAS No: 7440-46-2 | GMP-certified suppliers
A medication that provides localized radiation therapy for head and neck cancer through investigational cesium-based brachytherapy implants.
Therapeutic categories
Product Snapshot
- Cesium is formulated as an oral small molecule API
- It is primarily investigated for therapeutic uses in oncology and cardiovascular conditions
- The product is currently in the investigational stage with no approved regulatory status
Clinical Overview
Cesium belongs to the class of homogeneous alkali metal compounds, characterized by containing only metal atoms with the largest atom being from the alkali metal group. As a chemical element, cesium’s pharmacological profile as a drug entity is not fully established, and typical pharmacodynamic and mechanistic data are not available. Its clinical application in brachytherapy primarily exploits its radioisotopic properties rather than pharmacologic activity.
Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) parameters are not conventionally applicable to elemental cesium used in this investigational radiation context. The radioactive isotope’s decay characteristics and radiation dosimetry are critical for therapeutic efficacy and safety rather than traditional systemic exposure metrics.
Safety and toxicity considerations focus primarily on radiation exposure risks and control procedures, necessitating precise dosing, placement, and monitoring to mitigate radiation-induced tissue damage beyond the target site. Handling and preparation require strict adherence to radiopharmaceutical safety guidelines to protect healthcare personnel and patients.
Currently, cesium-based brachytherapy products such as cesium-131 seeds are investigational and used predominantly in specialized clinical settings. There are no broad regulatory approvals or marketed pharmaceutical formulations of elemental cesium outside investigational contexts.
For API sourcing, quality control must ensure radionuclidic purity, specific activity, and absence of chemical impurities. Suppliers should comply with Good Manufacturing Practices (GMP) pertinent to radiopharmaceutical materials and provide thorough documentation of isotope characterization and stability to support clinical use.
Identification & chemistry
| Generic name | Cesium |
|---|---|
| Molecule type | Small molecule |
| CAS | 7440-46-2 |
| UNII | 1KSV9V4Y4I |
| DrugBank ID | DB15392 |
Formulation & handling
- Cesium is a small molecule alkali metal compound with negligible water solubility, requiring formulation strategies to enhance bioavailability for oral or injectable use.
- The compound's inorganic nature suggests stability under standard handling conditions but low solubility necessitates consideration of suspension or complexation approaches.
- Due to its investigational status, detailed stability and sensitivity profiles are not established, highlighting the need for thorough characterization during development.
Regulatory status
Cesium is a type of Alkalinizing agents
Alkalinizing agents, a pharmaceutical API category, refers to a group of substances used to increase the pH (alkalinity) of a solution or body fluid. These agents play a crucial role in various medical applications, such as the treatment of acidosis, kidney disorders, and certain drug overdoses.
One commonly used alkalinizing agent is sodium bicarbonate, which is highly effective in raising the pH of blood and urine. It works by neutralizing excess acid and restoring the acid-base balance in the body. Sodium bicarbonate is often administered intravenously in emergency situations to rapidly correct severe acidosis.
Another alkalinizing agent, acetazolamide, is frequently employed in the treatment of glaucoma and certain types of epilepsy. By inhibiting carbonic anhydrase, acetazolamide reduces the production of bicarbonate ions, leading to a systemic decrease in pH. This mechanism is particularly useful in lowering the intraocular pressure associated with glaucoma.
Alkalinizing agents are also utilized in the management of certain drug toxicities. For instance, methotrexate, a chemotherapy medication, can cause severe toxicity if its elimination is hindered. Alkalinizing the urine with agents like sodium bicarbonate enhances methotrexate solubility, preventing the formation of toxic crystals in the kidneys.
In conclusion, alkalinizing agents are indispensable pharmaceutical APIs that help correct acid-base imbalances, treat specific medical conditions, and mitigate drug toxicities. Their diverse applications make them valuable tools in modern medicine.
